Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

ARWR | NASDAQ
Chart Builder DCF Calculator
$44.21
-$3.57 (-7.47%)
At close: Nov 16, 2026, 4:00 PM ET
$43.85
-$0.36 (-0.81%)
After-hours: Nov 16, 2026, 7:56 PM ET
-7.47%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
25.4
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #920/1021 (Top 90%)

Key Statistics

Market Data

Market Cap $6.25B
1D Range
44.08 47.41
52W Range
38.09 89.59

Valuation (TTM)

PE -8.67
PB 124.22
EV/EBITDA -9.66

Valuation (NTM)

Forward PE N/A
Forward PEG -0.18
Price Target $117.50
Loading financial charts...

Profile

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challeng...

Sector Healthcare
Industry Biotechnology
Employees 711
IPO Date Dec 16, 1993
Fiscal Year October - September

Latest News

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript

4 days ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights

4 days ago · marketbeat.com

Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences

7 days ago · businesswire.com

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

9 days ago · businesswire.com

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

13 days ago · businesswire.com

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

15 days ago · businesswire.com

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript

1 month ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

2 months ago · seekingalpha.com

Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands

2 months ago · marketbeat.com

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

2 months ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Earnings

Latest Earnings
Nov 12, 2026
EPS
-$3.04
Miss -100.00%
REV
$37.79M
Miss -38.23%
Next Earnings
Feb 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$117.50
Upside
+165.78%
Buy (8)
Hold (3)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.